STRATEC SE

Investor Presentation • May 7, 2021

STRATEC Q1 2021 FINANCIAL RESULTS

Birkenfeld, 2021-05-07

Forward-looking statements involve risks.

This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.

It is not planned to update these forward-looking statements.

1. Q1 2021 AT A GLANCE

• 1. FINANCIAL REVIEW
• 1. OUTLOOK
• 1. Q&A
• 1. APPENDIX

• • Sales up by 32.5% at constant exchange rates to € 72.0 million (Q1 2020: € 56.5 million) nominal growth of 27.4%

• -Double digit growth rates in all three segments (Instrumentation, Diatron and Smart Consumables)
• • Adjusted EBIT more than doubled to € 16.0 million (Q1 2020: 7.7 € million)
• -Adjusted EBIT margin up by 870 bps yoy to 22.3% (Q1 2020: 13.6%)
• •Achievement of important development milestones
• • Continuously high demand and positive customer feedback for STRATECs proprietary random access immunoassay platform KleeYa®
• First partner is expected to launch within the coming months
• -Numerous contract negotiations/etc ongoing

1. Q1 2021 AT A GLANCE

• 1. FINANCIAL REVIEW
• 1. OUTLOOK
• 1. Q&A
• 1. APPENDIX

FINANCIALS AT A GLANCE

€ 0 0 0s	Q 1 2 0 2 1	Q 1 2 0 2 0	C ha ng e
Sa les	7 1, 9 9 5	5 6, 5 0 4	2 7. 4 % +
E B I T D A	1 8, 8 4 0	1 0, 1 4 2	8 8 % 5. +
E B I T D A ( % ) in m ar g	2 6. 2	1 7, 9	8 3 0 bp + s
A d d E B I T j te us	1 6, 0 4 5	6 8 7, 5	1 0 9. % 5 +
A d d E B I T ( % ) j in te us m ar g	2 2. 3	1 3. 6	8 7 0 bp + s
A d d l da d j i inc te te t us co ns o ne om e	1 3, 1 4 7	2 6, 2 4 6	1 1 0. 5 % +
( € ) A d d ba ha j ic ing in te us s ea rn s p er s re	1. 0 9	2 0. 5 2	1 0 9. 6 % +
Ba ha I F R S ( € ) ic ing in s ea rn s p er s re	0. 9 5	2 0. 3 7	1 5 6. 8 % +

bps = basis points

For comparison purposes, adjusted figures exclude amortization resulting from purchase price allocations in the context of acquisitions.

2Result from continuing operations.

FINANCIAL REVIEW

SALES

In € million

Q1 2021 sales up 27.4% yoy to € 72.0 million +32.5% at constant currency

(+) Continuously high demand for molecular and immunoassay solutions

• Strong business with Systems as well as Service parts & Consumables
• (+) Single-digit growth with Development and Services sales
• (-) Ramp-up curve of newly launched products tampered by pandemic-driven reallocation of priorities

As of March 31

FINANCIAL REVIEW

ADJUSTED EBIT AND EBIT MARGIN

Q1 2021 adjusted EBIT up by 109.5% yoy to € 16.0 million

Q1 2021 adjusted EBIT margin up by 870 bps yoy to 22.3%

• (+) Economies of scale
• (+) Sales/product mix
• (+) Efficiency enhancements

As of March 31

FINANCIAL REVIEW

CASH FLOW AND NET DEBT

€ 0 0 0s	Q 1 2 0 2 1	Q 1 2 0 2 0	C ha ng e
Ca f h lo ing iv i ies t t t s er a a c w op –	4. 0 1	3. 2	3 3 % 7. 5 +
Ca h f lo inv iv i ies tm t a t t s es en c w –	3 4. -	7. 1 -	/a n
Ca f f h lo ina ing iv i ies t t s w nc a c –	3 1. -	4. 1 5	/a n
f Fr h lo ee c as w	9. 7	3. 9 -	/a n

€ 0 0 0s	Q 1 2 0 2 1	F Y 2 0 2 0	C ha ng e
Ca h d h len iva ts s an ca s eq u d f p d io t e a n er o	4 5. 7	3 7. 6	2 1. 5 % +
Eq ( % ) i io ty t u ra	5 1. 3	5 2. 0	7 0 bp s -
N de b t t e	7 5. 7	8 2. 7	8. 5 % -

• • Strong improvement in operating cash flow dynamics but still elevated inventory needs
• • Lower investment spending following completed construction work for expansion of building capacity at HQ (investment ratio¹ at 6.0% of sales)
• • Net debt down by 8.5%Net debt / LTM EBITDA of 1.2x

1 Total investments in intangible and tangible assets in % of salesLTM = Last twelve months

1. Q1 2021 AT A GLANCE

1. FINANCIAL REVIEW

3. OUTLOOK

• 1. Q&A
• 1. APPENDIX

FINANCIAL GUIDANCE FOR FISCAL YEAR 20211

• •Constant-currency sales growth in at least a high single-digit percentage range
• •Adjusted EBIT margin of around 17.5% to 18.5% (2020: 16.7%)
• •Investments in tangible and intangible assets combined of around 6.0% to 8.0% of sales

1 Due to the COVID-19 pandemic, STRATEC continues to observe higher volatility in its customers' order behavior. In the first quarter of 2021, the company witnessed an overall rise in order forecasts for the second half of 2021. Due to the additional forecasting uncertainties resulting from the pandemic, however, the higher order forecasts for the fourth quarter of 2021 in particular are still not incorporated in the above financial guidance.

FOCUS IN 2021 AND BEYOND

• • Drive forward development program for next-generation MDx solution for one of the dominant market players
• •Focus on potential M&A activities in-light of solid balance sheet and upcoming opportunities
• • Sign further development and manufacturing agreements
• Two bigger deals in the final negotiation stage
• •Manage transition to post-pandemic priorities

QUESTIONS& ANSWERS

Q1 2021 FINANCIAL RESULTS – MAY 7, 2021 ¹³

APPENDIX

ADJUSTMENTS

EBIT

€ 0 0 0s	Q 1 2 0 2 1	Q 1 2 0 2 0
A d j d E B I T te us	6, 0 4 1 5	6 8 7, 5
A d j tm ts us en :
P P A iza io t t am or n	-1 9 1 7 ,	-2 0 6 2 ,
E B I T	4, 2 8 1 1	9 6 5, 5

Consolidated net income

€ 0 0 0s	Q 1 2 0 2 1	1 Q 1 2 0 2 0
A d j d l i da d in te te t us co ns o ne co m e	1 3, 1 4 7	6, 2 4 6
j in in € A d d ha te us ea rn g s p er s re ( ba ic ) s	1. 0 9	0. 5 2
A d j tm ts us en :
P P A iza io t t am or n	-1 9 1 7 ,	-2 0 6 2 ,
Ta inc xe s o n om e	3 1 9	3 2 0
Co i in l da d te t ns o ne co m e	1 1, 5 4 9	4, 5 0 3
Ea in ha in € ( ba ic ) rn g s p er s re s	0. 9 5	0. 3 7

Results from continuing operations

CONTACT

STRATEC SEGewerbestr. 3775217 BirkenfeldGermany

Phone +49 7082 7916-0Fax +49 7082 7916-999www.stratec.com

CONTACT

Jan Keppeler, CFA Head of Investor Relations & Corporate Communications

Phone +49 7082 7916-6515 j.keppeler@stratec.com

THANK YOU FOR YOUR ATTENTION